17 July 2021 - Pfizer has agreed to pay $345 million to resolve claims by consumers who say they overpaid for EpiPens due to anticompetitive practices by the drug maker and the company that markets the emergency allergy treatment, Mylan.

The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas. 

The deal, which requires a judge's approval, would not resolve claims against Mylan, which is scheduled to face trial in January.

Read Reuters article